<?xml version="1.0" encoding="UTF-8"?>
<p>Despite similar rates of CRF02_AG found in both settings, the rural setting showed two more genetic variant [8 subtypes; A
 <sub>1</sub> (3), G (1), F
 <sub>2</sub> (1), CRF02_AG (21), CRF06_cpx (1), CRF11_cpx (1), and CRF18_cpx (1) and an unclassified recombinant of A
 <sub>1</sub>/F
 <sub>2</sub> (1)], compared to the Urban setting [5 subtypes A
 <sub>1</sub> (3), G (3), F
 <sub>2</sub> (1), CRF02_AG (23) and CRF18_cpx (1)]. The prevalence 
 <xref ref-type="fig" rid="pone.0235958.g001">Fig 1</xref> shows the phylogenetic tree of the entire study sequence analysed. However the study found no association between subtype distribution (CRF02_AG vs Non-CRF02_AG) and the occurrence of PDR mutation [CRF02_AG [9.1% (4/44)], Non-CRF02_AG [11.8% (2/17)]; 
 <italic>p</italic> = 1.000], as shown in 
 <xref rid="pone.0235958.t002" ref-type="table">Table 2</xref>. Moreover patients with CD4&lt;200 cells/mm
 <sup>3</sup> were found to have a higher PDR prevalence rate [14.7% (5/34)] as compared to those with CD4 â‰¥ 200 cells/mm
 <sup>3</sup>, however there was no significant association between CD4 staging and the occurrence of drug resistant mutation [3.7% (1/27)]; 
 <italic>p</italic> = 0.214] (
 <xref rid="pone.0235958.t002" ref-type="table">Table 2</xref>)
</p>
